Liminatus Pharma (NASDAQ:LIMN) Posts Earnings Results

Liminatus Pharma (NASDAQ:LIMN) released its earnings results on Tuesday. The company reported ($0.34) EPS for the quarter, FiscalAI reports.

Liminatus Pharma Stock Performance

Shares of NASDAQ:LIMN traded down $0.01 during midday trading on Tuesday, reaching $0.17. The company had a trading volume of 1,711,803 shares, compared to its average volume of 1,549,055. The company has a fifty day simple moving average of $0.48 and a two-hundred day simple moving average of $0.88. The firm has a market cap of $5.34 million and a price-to-earnings ratio of -1.43. Liminatus Pharma has a 1-year low of $0.17 and a 1-year high of $33.66.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Liminatus Pharma in a research report on Friday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.